Resection of hepatocellular carcinoma with macroscopic vascular invasion.

PubWeight™: 1.65‹?› | Rank: Top 3%

🔗 View Article (PMID 23884750)

Published in Ann Surg Oncol on July 25, 2013

Authors

Sasan Roayaie1, Ghalib Jibara, Bachir Taouli, Myron Schwartz

Author Affiliations

1: Mount Sinai Liver Cancer Program, Mount Sinai Medical Center, New York, NY, USA, sasan.roayaie@mssm.edu.

Articles citing this

Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) (2015) 1.88

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23

2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14

The ALPPS procedure: a surgical option for hepatocellular carcinoma with major vascular invasion. World J Surg (2014) 1.01

Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol (2015) 0.98

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis. World J Gastroenterol (2015) 0.85

Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett (2016) 0.81

Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. J Gastroenterol Hepatol (2016) 0.80

Outcomes of surgical resection and loco-regional therapy in patients with stage 3A hepatocellular carcinoma: a retrospective review from the national cancer database. HPB (Oxford) (2015) 0.78

Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer (2016) 0.78

"Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China. World J Gastroenterol (2013) 0.76

Development of a prognostic scoring system for resectable hepatocellular carcinoma. World J Gastroenterol (2016) 0.75

When does invasion mean the war is lost? Ann Surg Oncol (2013) 0.75

Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis. Biomed Res Int (2016) 0.75

Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Onco Targets Ther (2016) 0.75

Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis. Oncotarget (2016) 0.75

New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol (2017) 0.75

New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch. Surg Today (2017) 0.75

Nomograms to Predict the Individual Survival of Patients with Solitary Hepatocellular Carcinoma after Hepatectomy. Gut Liver (2017) 0.75

Articles by these authors

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology (2008) 2.34

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32

Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29

Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18

Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology (2015) 2.11

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98

Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging (2010) 1.96

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging. J Magn Reson Imaging (2010) 1.70

Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg (2012) 1.70

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66

Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience. Radiology (2008) 1.62

Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) (2010) 1.59

Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience. Eur J Radiol (2012) 1.58

Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg (2015) 1.53

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52

Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) (2013) 1.50

Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology (2009) 1.48

The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. Transpl Int (2010) 1.48

Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl (2004) 1.44

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44

Comprehensive preoperative evaluation and repair of inguinal hernias at the time of open radical retropubic prostatectomy decreases risk of developing post-prostatectomy hernia. BJU Int (2012) 1.39

Variability of renal apparent diffusion coefficients: limitations of the monoexponential model for diffusion quantification. Radiology (2010) 1.38

Comparison of biexponential and monoexponential model of diffusion weighted imaging in evaluation of renal lesions: preliminary experience. Invest Radiol (2011) 1.37

Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging (2011) 1.34

Diffusion-weighted imaging of the liver with multiple b values: effect of diffusion gradient polarity and breathing acquisition on image quality and intravoxel incoherent motion parameters--a pilot study. Radiology (2012) 1.31

Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol (2009) 1.23

MR findings in knee osteoarthritis. Eur Radiol (2002) 1.21

Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection. AJR Am J Roentgenol (2010) 1.18

Liver lesion detection and characterization: role of diffusion-weighted imaging. J Magn Reson Imaging (2013) 1.11

Diagnosis of liver fibrosis and cirrhosis with diffusion-weighted imaging: value of normalized apparent diffusion coefficient using the spleen as reference organ. AJR Am J Roentgenol (2010) 1.11

Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09

Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). Gastrointest Endosc (2012) 1.09

Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. Cardiovasc Pathol (2008) 1.09

Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology (2006) 1.07

T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. Radiology (2009) 1.05

Hepatocellular carcinoma: detection with diffusion-weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology (2012) 1.03

Hepatocellular carcinoma: short-term reproducibility of apparent diffusion coefficient and intravoxel incoherent motion parameters at 3.0T. J Magn Reson Imaging (2014) 1.02

Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl (2009) 1.02

Perspectives on body MR imaging at ultrahigh field. Magn Reson Imaging Clin N Am (2007) 1.00

Second hepatic resection for recurrent hepatocellular cancer: a Western experience. J Hepatol (2010) 1.00

Biliary tract depiction in living potential liver donors: comparison of conventional MR, mangafodipir trisodium-enhanced excretory MR, and multi-detector row CT cholangiography--initial experience. Radiology (2004) 0.98

Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging (2010) 0.98

Opposed-phase MRI for fat quantification in fat-water phantoms with 1H MR spectroscopy to resolve ambiguity of fat or water dominance. AJR Am J Roentgenol (2006) 0.96

Identification of vertebral fractures in osteoporosis. Semin Musculoskelet Radiol (2002) 0.96

Body and cardiovascular MR imaging at 3.0 T. Radiology (2007) 0.96

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist (2005) 0.96

MRI of pelvic floor dysfunction: dynamic true fast imaging with steady-state precession versus HASTE. AJR Am J Roentgenol (2008) 0.96

Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol (2010) 0.96

Management of localized prostate cancer and an incidental ureteral duplication with upper pole ectopic ureter inserting into the prostatic urethra. Rev Urol (2008) 0.95

Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One (2012) 0.95

Abdominal 4D flow MR imaging in a breath hold: combination of spiral sampling and dynamic compressed sensing for highly accelerated acquisition. Radiology (2014) 0.94

Liver transplantation for neuroendocrine tumors. J Gastrointest Surg (2004) 0.93

Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol (2008) 0.93

Hepatic iron deposition in patients with liver disease: preliminary experience with breath-hold multiecho T2*-weighted sequence. AJR Am J Roentgenol (2009) 0.92

Diffusion and perfusion imaging of the liver. Eur J Radiol (2010) 0.92

Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant (2004) 0.91

Intrahepatic portal cavernoma as an indication for liver transplantation. Liver Transpl (2007) 0.91

Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91

Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol (2013) 0.91

Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl (2005) 0.90

Telangiectatic focal nodular hyperplasia: US, CT, and MR imaging findings with histopathologic correlation in 13 cases. Radiology (2003) 0.90

Diffusion-weighted MRI and liver metastases. Magn Reson Imaging Clin N Am (2010) 0.90

The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation. Clin Transplant (2004) 0.88

DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility. J Magn Reson Imaging (2013) 0.88

Dynamic contrast-enhanced MR imaging of the liver: current status and future directions. Magn Reson Imaging Clin N Am (2009) 0.88

Timing bolus dynamic contrast-enhanced (DCE) MRI assessment of hepatic perfusion: Initial experience. J Magn Reson Imaging (2009) 0.88

Resection of hepatocellular carcinoma without cirrhosis. Ann Surg (2012) 0.87

Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg (2003) 0.87

Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear β-catenin and glutamine synthetase positivity: case report and review of the literature. Am J Surg Pathol (2011) 0.87

Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis (2008) 0.87

Diffusion-weighted MR imaging for liver lesion characterization: a critical look. Radiology (2012) 0.86

Retracted Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology (2010) 0.86

Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. Surg Oncol (2013) 0.86

Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium. AJR Am J Roentgenol (2012) 0.85

Characterization of adrenal pheochromocytoma using respiratory-triggered proton MR spectroscopy: initial experience. AJR Am J Roentgenol (2009) 0.85

Establishing an international training program for surgical residents. J Surg Educ (2007) 0.85

Actual 10-year survival following hepatectomy for hepatocellular carcinoma. HPB (Oxford) (2013) 0.84

Cancer history and other personal factors affect quality of life in patients with hepatitis C. Health Qual Life Outcomes (2005) 0.84

Diffusion-weighted MR imaging of the kidneys and the urinary tract. Magn Reson Imaging Clin N Am (2008) 0.84

Primary hepatic signet ring cell neuroendocrine tumor: a case report with literature review. Semin Liver Dis (2010) 0.84

Carcinoma ex microcystic adenoma of the pancreas: a report of a novel form of malignancy in serous neoplasms. Am J Surg Pathol (2012) 0.83